Navigation Links
Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
Date:10/3/2007

SAN MATEO, Calif., Oct. 3 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing anti-inflammatory therapeutics for chronic and acute inflammatory diseases, announced today the completion of enrollment and patient dosing in its Phase II clinical study of its lead compound, A-002 for stable coronary artery disease. Data analysis is scheduled to be completed by the end of the year.

"We are pleased with the rapid enrollment of this study and look forward to reporting the results later this year," said Colin Hislop, M.D., Senior Vice President Clinical Development at Anthera Pharmaceuticals. "Previously reported results have been promising and we expect the results of our ongoing evaluation will help guide Phase III clinical trial design."

A-002 Clinical Trial Protocol

The PLASMA trial (Phospholipase Levels And Serological Markers of Atherosclerosis) is a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease. Subjects were randomized to receive four doses of A-002 or standard of care for up to eight weeks. The study was designed to investigate the safety and the efficacy of A-002 (a potent inhibitor of the human enzymes known as secretory phospholipase A2) on dyslipidemia (primarily Low Density Lipoprotein Cholesterol "LDL-C") and systemic inflammation (as measured by levels of C-Reactive Protein "CRP") in patients with stable coronary heart disease. Elevated levels of sPLA2 have been implicated in abnormal lipid metabolism, atherogenesis and vascular inflammation. The Company is scheduled to meet with the Food and Drug Administration in the fourth quarter for an end-of-Phase II meeting to obtain concurrence on the design of the Phase III program.

A-002 Once Daily Clinical Trial

Based on preliminary data from the PLASMA Phase II clinical trial, Anthera has initiated a follow up clinical study investigating the effect of Once-Daily A-002 on dyslipidemia (primarily LDL-C) and systemic inflammation in a similar cardiovascular patient population. The trial expects to enroll 120 patients at 15 US sites and patients will be randomized to receive either A-002 (one of two doses) or placebo for eight weeks.

"Preliminary data analysis from our original PLASMA study, which employed twice daily dosing of A-002, suggests that a single daily dose may be sufficient to suppress sPLA2 for up to 24 hours. We look forward to further exploring this opportunity to improve patient convenience," said Jim Pennington, M.D., Chief Medical Officer and Executive Vice President of Anthera Pharmaceuticals. "We are hopeful these studies will provide additional clinical and scientific rationale to further develop A-002 in patients in need of novel therapies to improve their lipid profiles and reduce vascular damage due to inflammation."

Data analysis of the PLASMA Once-Daily Phase II trial is expected to be completed in early 2008. Anthera anticipates the A-002 Phase III program will target patients with coronary heart disease, with associated hyperlipidemia and inflammation who are currently not achieving adequate cholesterol control with diet, exercise, and existing statin therapies such as Lipitor(R). The Phase III program is scheduled to begin during the first half of 2008.

Further information about Anthera's clinical trials and sPLA2 can be found at http://www.PLASMAtrial.com or http://www.anthera.com.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held pharmaceutical development company committed to developing and commercializing clinical products that address unmet medical needs of patients with life-threatening chronic and acute inflammatory diseases. The Company has acquired from Eli Lilly and Company and Shionogi & Co. Ltd. worldwide rights (except Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase A2 (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a variety of diseases. For more information please visit http://www.anthera.com.

Contact:

Press Relations

(650) 931-8868

pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):